Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

 is a board-certified dermatologist and fellowship-trained pediatric dermatologist specializing in allergic contact dermatitis and occupational dermatitis in adults and children at Massachusetts General Hospital in Boston. He is actively involved in the American Contact Dermatitis Society in which he serves on the Pediatric Contact Dermatitis Working Group and the Interactive Media Committee. He is also an active member of the Society of Pediatric Dermatology, Pediatric Dermatology Research Alliance, and the American Academy of Dermatology

Articles

At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.

Reviewing the Multifactorial Nature of Chronic Hand Eczema and Upcoming Delgocitinib

professor and chair, department of dermatology, Director Temple Itch Center, Temple University Health System

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Chronic Itch Pathophysiology and Therapeutic Advances

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.



Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at the Yale School of Medicine in New Haven, Connecticut, and 

At RAD 2025, Christopher Bunick, MD, PhD, presented 6-month data from the CorEvitas AD Registry, highlighting clinically meaningful skin clearance, itch reduction, and more in bio-naïve and bio-experienced adults treated with upadacitinib. 

Late-Breaking Data: Real-World Registry Data Supports Upadacitinib Efficacy in Moderate to Severe AD, Regardless of Biologic History 

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of 

, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of 

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at 

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

PODCAST: From Infection to Innovation - The Turn Therapeutics Story

The aesthetics industry saw a massive boom during the COVID-19 pandemic for both invasive and non-invasive procedures. Amir Karam, M.D., San Diego, Calif., reveals what caused this increase in demand for aesthetics procedures and discusses the outlook for the future of the industry. 

The Cutaneous Connection- Episode 13: The COVID-19 Cosmetic Surgery Boom

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: June 5, 2025

Acne is increasingly recognized as a chronic condition, affecting diverse populations and demanding innovative treatment strategies and equitable care access.

The Growing Burden of Acne in America: Time to Rethink Our Approach

Daily Derm Times: June 4, 2025

Discover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.

Examining the Halfway Mark of 2025 in Dermatology

This review of the latest dermatologic studies includes insights into clinical manifestations of mpox infection, therapeutic modulation of Demodex density via isotretinoin, and more.

Journal Digest: June 4, 2025

In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.

Calling for Collective Investment and Action in Lichen Planus Care

, Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, emphasized the urgent need for industry involvement, organized advocacy, and collaborative action to improve outcomes for patients with lichen planus.

This latest discussion builds on prior conversations: 

, which spotlighted screening practices and disparities in care; and 

, which focused on therapeutic trends and treatment gaps based on findings from a large cross-sectional survey of more than 400 dermatology clinicians.

Now, Friedman broadens the lens to examine what must happen next.

“To me, this study is a call to action,” Friedman said, “because there are so many different gaps and the need is quite clear.”

, revealed widespread variability in clinical practices, a lack of standardized protocols, and inconsistent use of emerging treatments. For Friedman, these findings signal not only a therapeutic vacuum but also a communitywide opportunity.

“I think there are a couple different ways that we as a community can go about better helping our colleagues,” he says, “but ultimately helping patients...with lichen planus.”

Friedman is candid about the role pharmaceutical companies must play to move the needle in lichen planus care.

“I think first and foremost, though—and this is just being perfectly open and transparent—when industry pays attention to a disease, the wheels start turning,” he says. “It’s just the way of the world. It’s just a reality.”

He points to progress in other conditions as precedent: “We’ve seen that with atopic [dermatits]. We’ve seen that with hidradenitis [suppurativa]. We’re now seeing it with chronic spontaneous urticaria.”

The challenge, then, is how to get lichen planus on the radar of biotech and pharma leaders. 

“First things first, we need our industry partners to be invested,” Friedman said. “And maybe that’s on us to get them excited about it.”

Building the Framework: Societies, Podiums, and Guidelines

Beyond industry, Friedman believes medical societies must also rise to the occasion.

“Maybe it’s our dermatologic societies, like the American Academy of Dermatology,” he said. “Or maybe smaller regional societies that can make sure that lichen planus is front and center with podium time.”

He envisions tangible steps forward, such as the creation of a consensus statement or treatment guidelines.

“Those things take a lot of time and energy,” he said, “but I think that we have to do something.”

“There’s not a one-size-fits-all,” Friedman said. “But I think that we need some parallel tracks happening simultaneously to make sure that we are really following the evidence.”

The evidence base for lichen planus, he says, remains limited. He also emphasized the importance of identifying specific patient subgroups that might respond better to certain treatments. 

Friedman’s tone balances urgency with optimism: “We can get together and advocate for these patients. We have to tap into that industrial interest. I think that will then trickle down to the rest: the community.”

Study reveals gaps in screening and treatment practices for a chronic inflammatory skin condition among US dermatologists. News release. George Washington University. April 25, 2025. Accessed June 2, 2025. 

https://mediarelations.gwu.edu/study-reveals-gaps-screening-and-treatment-practices-chronic-inflammatory-skin-condition-among-us

Vidal SI, Menta N, Friedman A. Lichen planus: a cross-sectional evaluation of US dermatologists’ comorbidity screening and management patterns. 

Videos

In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.

Bridging the Gaps in Lichen Planus Treatment: Emerging Therapies and Clinical Realities

In the second part of his conversation with 

, Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, discusses what dermatologists are using to treat lichen planus and where the treatment landscape still falls short.

The new data come from a recent cross-sectional survey published in 

 that explored how more than 400 dermatology clinicians manage lichen planus, a chronic inflammatory condition with no FDA-approved therapies. 

, which focused on screening practices and disparities in lichen planus management, highlighted a “wild west” mentality in care delivery due to lack of clinical guidelines or consistent evidence-based protocols.

Now, in part 2, Friedman turns his attention to therapeutic choices: what clinicians are using, what’s missing, and why change is on the horizon.

“From our study, we know that the majority of dermatologists or residents or APPs are using topical corticosteroids—over 90%—as well as some of the non-steroidal options like calcineurin inhibitors [and] PDE4 inhibitors,” Friedman explained. “So that’s great for mild disease.”

But once the disease becomes moderate to severe, treatment practices become more variable.

Although oral retinoids like acitretin and isotretinoin have shown promise for more severe cases of lichen planus, the study found that many dermatology clinicians are still not utilizing these options widely.

“We actually ran a similar study several years ago that we presented at an annual AAD meeting,” Friedman noted. “The number of individuals who said they were using oral retinoids…practically doubled from several years ago. So A+ on that front, but still a lot of work to be done.”

Among oral immunosuppressants, methotrexate was reported as the most frequently used option. Yet even this choice is overshadowed by newer, more targeted therapies that remain largely inaccessible or underutilized.

“We are in an era of really fun toys,” Friedman said, referring to the emergence of biologics, JAK inhibitors, and other small-molecule treatments. “There is growing evidence that targeting interleukin-17 [and] JAK inhibition could be very potent with respect to managing moderate to severe disease with probably less baggage than some of the traditional oral immunosuppressants.”

Despite this promise, very few survey respondents reported using these advanced agents.

The absence of FDA-approved options for lichen planus remains a hurdle, leaving clinicians to rely heavily on off-label use. Even with these incremental advances, the question remains: How can the dermatology community do better?

Friedman believes the solution lies in organized collaboration.

“I think that comes down to us taking the initiative, maybe forming a society, or at least some type of task force-ish thing, that really relies on expertise to push out the right information that is based on the evidence to our colleagues,” he said.

That call to action echoes his earlier remarks about the “wild west” nature of lichen planus care. While enthusiasm for new tools is building, standardized guidelines remain absent. Until then, Friedman is encouraging his peers to stay curious, stay informed, and advocate for progress. 

“There’s still a lot of work to be done,” he said. “But I’m hopeful.”

Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.

Adam Friedman, MD, FAAD: Spotlighting Disparities in Lichen Planus Screening and Treatment

, Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, shared insights from a new study examining how US dermatologists screen for and manage lichen planus.

 surveyed more than 400 dermatologists and uncovered wide variation in clinical practices, especially regarding screening for comorbidities and treatment approaches for this chronic inflammatory skin condition.

“I love me some lichen planus,” Friedman said. “I've thought a lot about why that's the case. I think it's because it's kind of [the] Wild West. We do not have management guidelines. There are no FDA-approved therapies. That offers a fun challenge for me and my colleagues to take care of a really disabling, chronic inflammatory skin disease.”

This “Wild West” mentality, he explained, has created a scenario in which care is driven more by individual clinical training and subjective experience than evidence-based standards. 

The primary aim of the study was to “put a finger on the pulse” of how the dermatology community screens for comorbidities, Friedman explained. With emerging data linking lichen planus to a variety of systemic issues from thyroid disease to hypertension and psychosocial conditions, Friedman and his team wanted to understand how these risks were being addressed in practice.

“Right off the bat, a glaring gap was identified, which was that roughly a third of the 400-plus respondents [who] did participate in the study didn't screen for anything,” he said.

Historically, dermatologists have been taught to screen for hepatitis C when managing lichen planus, based on older associations and select studies, he added. 

“When I was in my training, I remember very distinctly that if you see lichen planus, assume hepatitis, or you have to screen for hepatitis at a bare minimum,”  Friedman said. “Now that's actually not necessarily correlated to what we're seeing epidemiologically. It's really more oral erosive lichen planus.”

In the study, those who screened for comorbidities most commonly looked for hepatitis C, followed by hepatitis B. Yet the incidence of the infection in patients with lichen planus was actually quite low, Friedman emphasized.

Meanwhile, screening for more prevalent and clinically relevant comorbidities such as hypertension, anxiety, and depression was frequently missed, despite their higher incidence rates in patients with lichen planus.

A Treatment Landscape Without FDA Guidance

Treatment approaches for lichen planus were equally varied. The vast majority of respondents reported relying on topical corticosteroids. Far fewer opted for systemic immunosuppressive agents or phototherapy, despite these approaches being supported by clinical evidence.

“These findings underscore the absence of standardized, evidence-based guidelines for lichen planus care,” Friedman said. “Practitioners are often left to rely on training background and personal experience, leading to wide variations in care and, ultimately, potential disparities in patient outcomes.”

Friedman believes these data serve as a crucial starting point for developing better protocols and, eventually, official treatment guidelines. “I know what I do, but I think it's great to have an understanding of what's going [on] out there to direct future efforts for, whether they're management strategies or guidelines,” he said.

More awareness, more research, and more structured approaches are needed, Friedman concluded.

, Anastasia Georgievskaya, CEO and co-founder of Haut.AI, shares the exciting future of 

, the AI-driven platform that simulates skincare ingredient effects using data-powered visualizations. Following the success of its initial release, which included 12 clinically supported ingredients, the platform is now poised for major expansion.

“After the launch, we got a lot of feedback. People were sending us emails, and also our collaborators and scientific partners were sending us a lot of great ideas,” Georgievskaya said.

Anastasia Georgievskaya reflects on the success of SkinGPT and reveals upcoming plans and potential advancements in artificial intelligence and dermatology.

he Future of AI-Powered Skincare

She revealed that new ingredients will soon be added, especially those emerging in the beauty space that patients are curious about but often don’t fully understand. The platform is also evolving to educate users on environmental damage, such as UV exposure and pollution, and the long-term effects these external factors can have on skin health. Another new feature will be the simulation of ingredient combinations. This will aim to help patients recognize common or past mistakes in their own skincare routines and adjust accordingly, as certain ingredients and multiple actives may be causing more harm than good.

“So, we hope to bring more awareness, education, and essentially also introduce little fun moments so you can try all of the ingredients from the comfort of your home [without] buying a lot of the products,” Georgievskaya said.

Looking further ahead, Georgievskaya envisions a broader role for generative AI in dermatology. Similar to wearable health technology like Oura Ring or Apple Watch, she sees potential in using AI to collect and analyze massive amounts of skin-related data. This could lead to predictive insights into why skin behaves in a certain way, particularly as skin is influenced by stress, hormones, environment, and lifestyle.

Georgievskaya can also imagine a dermatology-specific version of ChatGPT that relies on real clinical practice and patient data, contributed by licensed dermatologists, estheticians, and surgeons. Patients could potentially ask their questions to this system in a safe, anonymized way that is rooted in validated medical expertise and knowledge. These innovative advancements in artificial intelligence may be able to support personalized, data-driven dermatological care, especially for chronic conditions like rosacea and acne.

“I'm really excited that technology emerges and helps us manage this, helps us explain what's going on, gives us some factual data,” she concluded. “I’m excited for what's coming in AI next from Haut.AI and other beauty tech companies.”

Generative Skin, an AI-driven platform by Haut.AI, is set for expansion, adding new skincare ingredients and features to educate users on environmental damage and ingredient combinations. The platform aims to enhance user awareness and allow experimentation with skincare products virtually. CEO Anastasia Georgievskaya envisions AI's broader role in dermatology, akin to wearable health tech, for predictive skin insights. She also foresees a dermatology-specific AI system for patient queries, leveraging clinical data. These advancements could revolutionize personalized dermatological care, particularly for chronic conditions.

The Future of AI-Powered Skincare

, Anastasia Georgievskaya, CEO and co-founder of Haut.AI, introduces Generative Skin, an interactive digital platform powered by 

 that aims to revolutionize how patients understand skincare ingredients and their effects. This new initiative combines clinical accuracy with unique artificial intelligence simulations, allowing patients to visualize how specific ingredients may impact their skin and address their concerns.

As a patient with rosacea herself, Anastasia Georgievskaya highlights the innovation of Generative Skin in patient education.

Treating Rosacea and Other Concerns with Generative Skin’s Ingredient Library

Generative Skin offers a comprehensive library of trendy and emerging skincare ingredients, backed by peer-reviewed clinical research. Visitors to the site can explore educational blogs, learn about 6 core skin concerns—including rosacea, acne, and hyperpigmentation—and try on ingredients like azelaic acid using AI-generated before-and-after imagery. This visual approach highlights ingredient efficacy and provides a much-needed bridge between clinical science and patient understanding.

Particularly relevant during Rosacea Awareness Month, Georgievskaya, who also lives with rosacea, emphasizes how empowering this tool can be for patients managing chronic conditions. For example, patients with rosacea often track flare-ups with personal photos, but may struggle to assess progress objectively. The portal offers a realistic, simulated view of how redness and inflammation may reduce over time with treatment. This helps patients distinguish between temporary changes and actual improvements, potentially reducing the emotional burden that often comes with visible, lifelong skin conditions.

“Just looking at your simulated photos with less redness or more redness can help in understanding that yes, it's a disease, but it's still okay and other people [also] have these concerns,” Georgievskaya said.

Generative Skin can also be used as a tool for managing expectations. By showing what changes can be realistically achieved over 2, 4, or 6 weeks, it helps users better understand timelines for visible results. This visual clarity can improve treatment adherence and support clinicians for the best possible long-term outcomes. Georgievskaya noted that patients are less likely to abandon a regimen prematurely when they understand that progress is gradual and personalized.

Anastasia Georgievskaya's Generative Skin platform, powered by SkinGPT, aims to transform patient understanding of skincare ingredients through AI simulations. It offers a comprehensive library of ingredients, backed by clinical research, allowing users to visualize potential effects on their skin. The platform is particularly beneficial for managing chronic conditions like rosacea, providing realistic simulations to track progress and manage expectations. By illustrating achievable changes over time, it enhances treatment adherence and supports clinicians in achieving optimal long-term outcomes for patients.

General Dermatology

Latest News